

Systematic Evidence Map (SEM) to Characterize Available Evidence for 9000 PFAS

Kristina Thayer CPHEA/CPAD Office of Research and Development

Executive Meeting | Board of Scientific Counselors September 29-30, 2021

The views expressed in this presentation are those of the author(s) and do not necessarily represent the views or policies of the U.S. Environmental Protection Agency.

Sepa Goals

- Use systematic review methods to identify and summarize animal bioassay and epidemiological evidence for ~9000 PFAS
 - Create a repository that is easily updated, web-based, and shareable
 - Focused on PFAS structures and substances listed in EPA CompTox Chemicals Dashboard
- Specific uses:
 - Identify *in vivo* evidence to inform CCTE efforts to characterize PFAS library
 - Characterize data gaps and key research needs
 - Be positioned to quickly address new PFAS assessment needs




- Systematic review methods used to search for, screen, and evaluate the relevant literature
 - Use machine-learning and automated approaches to develop search strategies
- Searches initiated in batches as they were identified of interest ("PFAS 150", "PFAS 430", "PFAS 9000")
 - List of 9,000 PFAS substances and structures includes most of the chemicals in the EPA CompTox chemicals dashboard (<u>https://comptox.epa.gov/dashboard/chemical_lists/PFASSTRUCT)</u>
- Study methods and findings summarized ("data extraction") and the results made available online as downloadable and interactive visual formats
- ADME studies*, PBPK models*, in vitro studies, and exposure-only human studies being tracked as supplemental material
- Cross-checked reference lists with other resources (e.g., ATSDR drafts)

*ADME = absorption, distribution, metabolism, and elimination; PBPK model = physiologically based pharmacokinetic model 3

Interactive Displays: Inventory

SEPA




Interactive Displays: Extraction

Chemical	Endpoint	Study	Animal Description	Route	Exposure Duration			Y -
6:2 Fluorotelomer alcohol	Liver Weight, Absolute	Mukerji et al. 2015	P0 Mouse, Crl:CD-1(ICR)BR (♀)	oral gavage	14d pre-mating, 14d mating, gestation, lactation	•	no apparent trea	hdpoint name
			P0 Mouse, Crl:CD-1(ICR)BR (ੋ)	oral gavage	109 d (premating-sacrifice)	••••	treatment-related	System
		Serex T et al. 2014	Rat, Crl:CD(SD) (우)	oral gavage	90 d			Organ
			Rat, Crl:CD(SD) (ೆ)	oral gavage	90 d	•• 🔺 🔺		Effect
		Unnamed report (2005a) (ECHA summary)	Rat, Crl:CD(SD) (ೆ⊋)	oral gavage	28 d	++		
	Liver Weight, Relative	Mukerji et al. 2015	P0 Mouse, CrI:CD-1(ICR)BR (\bigcirc	oral gavage	14d pre-mating, 14d mating, gestation, lactation	••		Effect subtype Diagnostic
			P0 Mouse, Crl:CD-1(ICR)BR (්)	oral gavage	109 d (premating-sacrifice)	•• <u>-</u>		description
		ECHA, 2007, 5701160	Rat, Crl:CD(SD) (♀)	oral gavage	28d (1dose/d)	*• ••		Observation time
		Serex T et al. 2014	Rat, Crl:CD(SD) (♀)	oral gavage	90 d	•• <u> </u>		
		ECHA, 2007, 5701160	Rat, Crl:CD(SD) (♂)	oral gavage	28d (1dose/d)	*• ••		Data reported?
		Serex T et al. 2014	Rat, Crl:CD(SD) (충)	oral gavage	90 d			Data extracted?
6:2 Fluorotelomer methacrylate	Liver Weight, Absolute	ECHA, 2007, 6299223	Rat, Crl:CD(SD) (♀)	oral gavage	28d (1dose/d)	••		
			Rat, Crl:CD(SD) (්)	oral gavage	28d (1dose/d)	••		Values estimated?
	Liver Weight, Absolute, Recovery	ECHA, 2007, 6299223	Rat, Crl:CD(SD) (♀)	oral gavage	28d (1dose/d)	••		Location in
			Rat, Crl:CD(SD) (්)	oral gavage		••		
	Liver Weight, Relative	ECHA, 2007, 6299223	Rat, Crl:CD(SD) (♀)	oral gavage	28d (1dose/d)	••		literature
			Rat, Crl:CD(SD) (♂)		28d (1dose/d)	••		Expected response adversity direction
	Liver Weight, Relative, Recovery	ECHA, 2007, 6299223	Rat, Crl:CD(SD) (♀)	oral gavage		••		
			Rat, Crl:CD(SD) (충)	oral gavage		••		
Trifluoroacetic acid	Liver Weight, Absolute	Unnamed Report (2010a) (ECHA Summary)	P0 Rat, Crl:CD(SD)IGS BR (♀)	oral gavage	GD 6-19	+++		
		Unnamed Report (2012b) (ECHA Summary)	P0 Rat, Crl:CD(SD)IGS BR (♀)	oral gavage	up to 57 d (premating-lactation)	•••	-	NEL
			P0 Rat, Crl:CD(SD)IGS BR (3)	oral gavage	38 d (premating-termination)	•• 🔺		LEL
		Saillenfait et al. 1997	P0 Rat, Sprague-Dawley (♀)	oral gavage	GD 10-20	• <u>^</u>		LEL
			F1 Rat, Sprague–Dawley (ని⊋)	oral gavage	GD 10-20	••••		
		Unnamed Report (2016a) (ECHA Summary)	Rat, Wistar Rj:Wi (lops Han) (우)	oral diet	90 d	•		Monotonicity
			Rat, Wistar Rj:Wi (lops Han) (♂)	oral diet	90 d	• 🔺 🚽		Trend result
	Liver Weight, Relative	Unnamed Report (2012b) (ECHA Summary)	P0 Rat, Crl:CD(SD)IGS BR (♀)	oral gavage	up to 57 d (premating-lactation)	•••		Results notes
			P0 Rat, Crl:CD(SD)IGS BR (්)	oral gavage	38 d (premating-termination)	•• <u> </u>		
		Saillenfait et al. 1997	P0 Rat, Sprague-Dawley (₽)	oral gavage	GD 10-20	↓ ◆ ▲ ▲		
			F1 Rat, Sprague–Dawley (ở♀)	oral gavage	GD 10-20	••••		
		Unnamed Report (2016a) (ECHA Summary)	Rat, Wistar Rj:Wi (lops Han) (우)	oral diet	90 d	•		A
			Rat, Wistar Rj:Wi (lops Han) (♂)	oral diet	90 d	0 100 200 3	00 400 500 600 71 Dose (mg/kg-day)	0 800 900 1,0001,100

SEPA

		ight, Absolute
		Details
ndpoint i	name	Liver Weight, Absolute
related System		Hepatic
Organ		Liver
Effect		Clinical Observation
Effect sub		Organ Weight
Diagnostio		Liver, Weight
Observati	on time	90 d
Data repo	rted?	✓
Data extra	cted?	✓
Values est	timated?	-
Location in literature	n	Table 5
Expected response adversity	direction	
NEL		25 mg/kg-day
LEL		125 mg/kg-day
Monotoni	city	-
Trend res	ult	not reported
Results no	otes	"Following 90 days of dosing, effects on organ weights were present in the testes, liver and kidney of males (Table 5) and in livers and kidneys
-	-	



Dataset


Dose (mg/kg- day)	Number of Animals	Response (g)	Standard Deviation
0	10	15.94	1.9
5	10	16.09	1.9
25ª	10	16.62	2.02
125 ^{b,c}	10	19.09	1.89
250 ^b	8	22.84	2.39
3.000 00 00 00 00			

^a NEL (No effect level) ^b Significantly different from control (p < 0.01)

^c LEL (Lowest effect level)

SEPA

Interactive Displays: Study Evaluation



Not reported

Not Reported (interpreted as Deficient). <u>Clinical signs</u>. The report did not indicate whether examiners were blinded to animals' exposure status for this outcome. Because this outcome can be subjective, assessor blinding is important.

Close

~

mmary) CHA sum

SEPA Findings to Date

- Many PFAS are data poor
 - PFAS 150: 136 animal studies for 35 PFAS, 166 human studies for 11 PFAS
 - PFAS 430: 341 unique chemicals searched that were not included in prior search; 142 had data
 - PFAS 9000: 9,266 PFAS chemicals were searched; 416 have records
- Data extraction has been extended to shorter-term studies (<1 month)
- When a specific PFAS is identified as of interest, additional higher level of effort steps are taken to identify evidence (i.e., availability of CBI studies)
- Very few inhalation toxicity studies available
 - ORD exploring approaches for extrapolating from oral administration studies



- PFAS 150: Manuscript submitted September 2021
- PFAS 430: Manuscript planned for FY22
 - 119 animal bioassay studies undergoing extraction and study evaluation; 48 human studies identified
- PFAS 9000: Screening underway
 - 26,000 records being screened at title and abstract level
- Overall goal is to create a single repository that can be readily updated

SEPA

Contributors

- Laura M. Carlson, CPHEA/HEEAD
- Michelle Angrish, CPHEA/CPAD
- Elizabeth G. Radke, CPHEA/CPAD
- Brittany Schultz, CPHEA/HEEAD
- Andrew Kraft, CPHEA/CPAD
- Avanti Shirke, CPHEA/CPAD
- Richard Judson, CCTE/BCTD
- Grace Patlewicz, CCTE/CCED
- Robyn Blain, ICF International Inc.

- Cynthia Lin, ICF International Inc.
- Nicole Vetter, ICF International Inc.
- Courtney Lemeris, ICF International Inc.
- Pamela Hartman, ICF International Inc.
- Heidi Hubbard, ICF International Inc.
- Xabier Arzuaga, CPHEA/CPAD
- Allen Davis, CPHEA/CPAD
- Laura V. Dishaw, CPHEA/CPAD
- Ingrid Druwe, CPHEA/CPAD

- Hillary Hollinger, CPHEA/HEEAD
- Ryan Jones, CPHEA/HEEAD
- J. Phillip Kaiser, CPHEA/CPAD
- Lucina Lizarraga, CPHEA/CPAD
- Pamela Noyes, CPHEA/CPAD
- Michele Taylor, CPHEA/CPAD
- Andrew J. Shapiro, CPHEA/HEEAD
- Antony J. Williams, CCTE/CCED
- Kristina A. Thayer, CPHEA/CPAD

Supported by Health and Environmental Risk Assessment